GE HealthCare Technologies Inc. (GEHC) AI Stock Analysis

GE HealthCare Technologies Inc. develops, manufactures, and markets products, services, and digital solutions for patient diagnosis, treatment, and monitoring. The company operates across four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment includes CT scanning, molecular imaging, MR imaging, image-guided therapy, X-ray systems, and women's health products. Ultrasound provides systems for radiology, primary care, cardiovascular health, and surgical guidance. Patient Care Solutions offers patient monitoring, anesthesia delivery, respiratory care, ECG, and maternal-infant care systems. Pharmaceutical Diagnostics supplies contrast media pharmaceuticals and molecular imaging agents for CT, MR, X-ray, and nuclear medicine scans.

Between FY2021 and FY2025, annual revenue increased from $17.59B to $20.62B, representing a 5-year CAGR of 3.7%. Operating margin stood at 15.9% in FY2021 and 13.4% in FY2025, while net margin went from 12.8% to 10.1%. Net income reached $2.08B in FY2025, compared to $2.25B in FY2021 and $3.10B in FY2023. Over the trailing twelve months, revenue totaled $21.27B with an operating margin of 15.0% and a net profit margin of 9.3%. In the latest quarter ending June 30, 2026, quarterly revenue growth was 5.8% year-over-year, while quarterly earnings grew 16.8%.

As of June 30, 2026, GE HealthCare Technologies held $2.10B in cash and short-term investments against $10.09B in total debt, leading to net debt of $7.99B. Total assets stood at $37.25B and shareholders' equity was $10.97B, resulting in a debt-to-equity ratio of 0.92 and a current ratio of 1.02. In FY2025, operating cash flow reached $1.99B and free cash flow was $1.51B. Capital allocation during FY2025 included $482.0M for capital expenditures, $200.0M for share buybacks, and $64.0M in dividends paid.

GEHC trades at a trailing P/E of 16.0x and a forward P/E of 12.1x, below the median of its Nasdaq-100 Healthcare peers of 34.1x and 23.0x, respectively. The company carries an enterprise value of $38.31B, yielding an EV-to-EBITDA multiple of 10.4x compared to 24.5x for the median of its Nasdaq-100 Healthcare peers. Its price-to-sales ratio is 1.5x and its PEG ratio is 1.65. Over the trailing year, the stock fell 5.0%, trailing the S&P 500 (SPY) gain of 16.8%.

GE HealthCare Technologies pays a quarterly dividend with an annual forward dividend of $0.16 per share, representing a dividend yield of 0.23%. The company maintains a dividend payout ratio of 3.1% and has paid dividends for 4 consecutive years. Its last ex-dividend date was October 23, 2026.

Wall Street analysts currently assign the stock 10 Strong Buy, 6 Buy, and 5 Hold ratings, with 0 Sell and 0 Strong Sell ratings. The mean price target is $82.70, which is 18.9% above the last close of $69.57. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $21.72B and EPS of $4.93, representing 7.3% EPS growth. The company has beaten EPS expectations in 3 of the last 4 quarters, and its next earnings date is October 28, 2026.

This page is an AI-written research summary of GE HealthCare Technologies Inc. (GEHC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GEHC income statement, GEHC balance sheet, GEHC key metrics, GEHC analyst forecast, GEHC chart. See the GEHC stock overview for the latest quote and news.